Advances in Allogeneic Hematopoietic Stem Cell Transplantation

ISBN-13: 9780792377146 / Angielski / Twarda / 2000 / 414 str.

Mary M. Brush; Richard K. Burt

Opis

The field of hematopoietic stem cell transplantation is rapidly evolving. Realization that hematopoietic stem cells give rise to the immune compartment has resulted in clinical trials of hematopoietic stem cell transplantation for patients with autoimmune diseases. Allogeneic hematopoietic transplants are a form of adoptive immunotherapy resulting in beneficial graft versus tumor effects. Large numbers of hematopoietic cells can be collected with ease. Therefore, a renewable source of cells for ex vivo genetic manipulations is readily available. Multiple trials combining hematopoietic transplants and gene therapy are in progress. One such application is the infusion of allogeneic lymphocytes containing a suicide gene to abort graft versus host disease. Hematopoietic stem cell transplantation is in reality the clinical and practical application of cellular therapy. Hematopoietic transplant physicians are by design or by practical application evolving into cell and gene therapy specialists. The excitement and enthusiasm in hematopoietic transplantation is that it offers a door to the future. A future not of drugs or titrating poisonous chemotherapy but rather of cellular and gene therapy. 1 ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC DISEASES Martin Korbling University o/Texas MD. Anderson Cancer Center, Houston, Texas 77030 INTRODUCTION Circulating hematopoietic stem cells have emerged as an alternative to bone marrow (BM) stem cells for allografting. For many years the reconstitutive potential of circulating stem cells was questioned; peripheral blood stem cells (PBSC) were even characterized a waste product (1).

Spis treści

Contributors. Preface. 1. Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Diseases; M. Körbling. 2. Unrelated Donor Marrow Transplantation for Treatment of Childhood Hematologic Malignancies Effect of HLA Disparity and Cell Dose; A.E. Woolfrey, et al. 3. Haploidentical Transplantation; P.J. Henslee-Downey. 4. Umbilical Cord Blood Hematopoietic Stem Cell Transplantation; E. Gluckman, et al. 5. Non Myeloablative `Mini Transplants'; S. Giralt, et al. 6. Allogeneic Hematopoietic Stem Cell Transplantation in Recipients of Cellular or Solid Organ Allografts; N.S. Kenyon, et al. 7. Allogeneic Peripheral Blood Progenitor Cell Transplantation in Solid Tumors; N.T. Ueno, et al. 8. Hematopoietic Stem Cell Transplantation of Multiple Sclerosis, Rheumatoid Arthritis, and Systemic Lupus Erythematosus; R.K. Burt, et al. 9. Advances in the Control of Cytomegalovirus Disease in Bone Marrow Transplant Patients; W.H. Burns. 10. Adoptive Immunotherapy for EBV-Associated Malignancies; K.G. Lucas, J.C. Barrett. 11. Adoptive Immunotherapy using Donor Leukocyte Infusions to Treat Relapsed Hematologic Malignancies After Allogeneic Bone Marrow Transplantation; W.R. Drobyski. 12. Clinical Use of Irradiated Donor Lymphocytes in Bone Marrow Transplantation; A.M. Ship, et al. 13. Dendritic Cells and Their Clinical Applications; D.N.J. Hart, G.J. Clark. 14. Engineering Hematopoietic Grafts Using Elutriation and Positive Cell Selection to Reduce GVHD; S.J. Noga. 15. Monoclonal Antibody and Receptor Antagonist Therapy for GVHD;J.L.M. Ferrara, et al. 16. Adoptive Immunotherapy for Leukemia: Donor Lymphocytes Transduced with the Herpes Simplex Thymidine Kinase Gene; C.J. Link, Jr., et al. 17. Clinical Application of Hematopoietic Stem Cell Culture and Expansion; S.G. Emerson, et al. 18. New Cytokines and Their Clinical Application; I.K. McNieze. Index.